Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VPS4B | O75351 | 1/20 | 1.00 |
| ▸ | VCP | P55072 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.47 |
| ▸ | DRD2 | P14416 | 14/20 | 0.47 |
| ▸ | HTR2B | P41595 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR1F | P30939 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905309 | 0.77 | VPS4B (0.61) | VPS4BVCPSLC6A4DRD2HTR2B | |
| SCHEMBL5384502 | 0.74 | VPS4B (0.58) | VPS4BVCPSLC6A4DRD2HTR2B | |
| SCHEMBL4900711 | 0.74 | VPS4B (0.58) | VPS4BVCPSLC6A4DRD2HTR2B | |
| SCHEMBL4900652 | 0.74 | VPS4B (0.58) | VPS4BVCPSLC6A4DRD2HTR2B | |
| SCHEMBL25488446 | 0.73 | VPS4B (0.57) | VPS4BVCPSLC6A4 | |
| SCHEMBL4904352 | 0.72 | VPS4B (0.56) | VPS4BVCPSLC6A4DRD2HTR2B | |
| SCHEMBL4904570 | 0.72 | VPS4B (0.55) | VPS4BVCPSLC6A4DRD2HTR2B | |
| SCHEMBL4899304 | 0.69 | HTR1B (0.52) | VPS4BVCPSLC6A4DRD2HTR1A | |
| SCHEMBL4895910 | 0.69 | HTR1B (0.52) | VPS4BVCPSLC6A4DRD2HTR1A | |
| SCHEMBL4897652 | 0.69 | HTR1B (0.52) | VPS4BVCPSLC6A4DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181528-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA | THE BROAD INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | claimed |
| US-20230146923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION AND TARGETING OF P97 | CALIFORNIA INST OF TECHN (US) | 2023-05-11 | — | — | US | claimed |
| EP-4161552-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA | The Broad Institute, Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| US-20230012420-A1 | METHODS AND COMPOSTIONS FOR INHIBITING P97 | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-01-12 | — | — | US | claimed |
| US-20230002774-A1 | METHODS AND COMPOSTIONS FOR INHIBITING CORONAVIRAL REPLICATION | CALIFORNIA INST OF TECHN (US) | 2023-01-05 | — | — | US | claimed |
| WO-2023278272-A1 | METHODS AND COMPOSTIONS FOR INHIBITING P97 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-01-05 | — | — | WO | claimed |
| CN-121534048-A | Application of MSC1094308 in preparation of medicine for preventing and/or treating inflammation small body related diseases | 山东大学 | 2026-02-17 | — | — | CN | disclosed |
| CN-121534048-A | Application of MSC1094308 in preparation of medicine for preventing and/or treating inflammation small body related diseases | 山东大学 | 2026-02-17 | — | — | CN | disclosed |
| EP-4683630-A1 | VPS4B INHIBITOR FOR USE IN METHODS FOR THE TREATMENT OF HRD CANCER | Institut Curie (FR) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024194401-A1 | VPS4B INHIBITOR FOR USE IN METHODS FOR THE TREATMENT OF HRD CANCER | INSTITUT CURIE (FR) | 2024-09-26 | — | — | WO | disclosed |
| US-20230181528-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA | THE BROAD INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230146923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION AND TARGETING OF P97 | CALIFORNIA INST OF TECHN (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4161552-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA | The Broad Institute, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20230012420-A1 | METHODS AND COMPOSTIONS FOR INHIBITING P97 | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-01-12 | — | — | US | disclosed |
| US-20230012420-A1 | METHODS AND COMPOSTIONS FOR INHIBITING P97 | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-01-12 | — | — | US | disclosed |
| US-20230002774-A1 | METHODS AND COMPOSTIONS FOR INHIBITING CORONAVIRAL REPLICATION | CALIFORNIA INST OF TECHN (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002774-A1 | METHODS AND COMPOSTIONS FOR INHIBITING CORONAVIRAL REPLICATION | CALIFORNIA INST OF TECHN (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2023278272-A1 | METHODS AND COMPOSTIONS FOR INHIBITING P97 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002774-A1 | METHODS AND COMPOSTIONS FOR INHIBITING CORONAVIRAL REPLICATION | SARS1, POLR2H, POLRMT | VPS4B 2349/4885VCP 785/4885SLC6A4 3807/4885 |
| US-20230012420-A1 | METHODS AND COMPOSTIONS FOR INHIBITING P97 | SMN1; SMN2, UBQLN2, PSMG3 | VPS4B 460/4885VCP 18/4885SLC6A4 3555/4885 |
| US-20230146923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION AND TARGETING OF P97 | HSP90B1, CDC37, HDLBP | VPS4B 920/4885VCP 29/4885SLC6A4 4250/4885 |
| US-20230181528-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA | VPS4B, ATG4A, ATG4B | VPS4B 1/4885VCP 224/4885SLC6A4 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.